NCT06895356View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

83

Participants

Timeline

Start Date

March 26, 2025

Primary Completion Date

June 16, 2025

Study Completion Date

June 16, 2025

Conditions

Healthy Volunteer

Interventions

DRUG

Tavapadon

Oral: Tablet

Trial Locations (1)

60030

Acpru /Id# 275870, Grayslake

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AbbVie

INDUSTRY